Micro-scale vertebral features in postmenopausal women with alcohol-associated and metabolic-associated fatty liver disease: ex vivo bone quality analyses.
Alcoholic liver disease
Bone quality
Lumbar vertebrae
Nonalcoholic fatty liver disease
Osteoporosis
Women
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
10 Jun 2023
10 Jun 2023
Historique:
received:
26
03
2023
accepted:
01
06
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
aheadofprint
Résumé
Although epidemiological studies indicate increased fracture risk in women with alcohol-associated liver disease (AALD) and metabolic-associated fatty liver disease (MAFLD), data about their micro-scale bone features are still limited. We aimed to characterize bone quality changes in the anterior mid-transverse part of the first lumbar vertebral body collected from 32 adult postmenopausal females. Based on pathohistological assessment of the liver tissue, individuals were divided into AALD (n = 13), MAFLD (n = 9), and control group (n = 10). We analyzed trabecular and cortical micro-architecture (using micro-computed tomography), bone mechanical properties (using Vickers microhardness tester), osteocyte lacunar network and bone marrow adiposity morphology (using optic microscopy). Data were adjusted to elude the covariant effects of advanced age and body mass index on our results. Our data indicated a minor trend toward deteriorated bone quality in MAFLD women, presented in impaired trabecular and cortical micro-architectural integrity, which could be associated with bone marrow adiposity alterations noted in these women. Additionally, we observed a significant decline in micro-architectural, mechanical, and osteocyte lacunar features in lumbar vertebrae collected from the AALD group. Lastly, our data indicated that vertebral bone deterioration was more prominent in the AALD group than in the MAFLD group. Our data suggested that MAFLD and AALD are factors that could play a part in compromised vertebral strength of postmenopausal women. Also, our data contribute to understanding the multifactorial nature of bone fragility in these patients and highlight the necessity for developing more effective patient-specific diagnostic, preventive, and therapeutic strategies.
Identifiants
pubmed: 37296370
doi: 10.1007/s40618-023-02130-3
pii: 10.1007/s40618-023-02130-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 200110
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Blachier M, Leleu H, Peck-Radosavljevic M et al (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608. https://doi.org/10.1016/j.jhep.2012.12.005
doi: 10.1016/j.jhep.2012.12.005
pubmed: 23419824
Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202–209. https://doi.org/10.1016/j.jhep.2020.03.039
doi: 10.1016/j.jhep.2020.03.039
pubmed: 32278004
Sun FR, Wang BY (2021) Alcohol and metabolic-associated fatty liver disease. J Clin Transl Hepatol 9:719–730. https://doi.org/10.14218/JCTH.2021.00173
doi: 10.14218/JCTH.2021.00173
pubmed: 34722187
pmcid: 8516839
Toshikuni N, Tsutsumi M, Arisawa T (2014) Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 20:8393–8406. https://doi.org/10.3748/wjg.v20.i26.8393
doi: 10.3748/wjg.v20.i26.8393
pubmed: 25024597
pmcid: 4093692
Yang YJ, Kim DJ (2021) An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia. Int J Mol Sci 22:1–33. https://doi.org/10.3390/ijms22052604
doi: 10.3390/ijms22052604
Lu K, Shi TS, Shen SY et al (2022) Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. Cell Metab 34:441-457.e7. https://doi.org/10.1016/j.cmet.2022.02.006
doi: 10.1016/j.cmet.2022.02.006
pubmed: 35235775
Wester A, Hagström H (2022) Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: a nationwide population-based cohort study. J Intern Med 292:492–500. https://doi.org/10.1111/joim.13497
doi: 10.1111/joim.13497
pubmed: 35373876
pmcid: 9545244
Bang CS, Shin IS, Lee SW et al (2015) Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. World J Gastroenterol 21:4038–4047. https://doi.org/10.3748/wjg.v21.i13.4038
doi: 10.3748/wjg.v21.i13.4038
pubmed: 25852292
pmcid: 4385554
Mantovani A, Dauriz M, Gatti D et al (2019) Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther 49:375–388. https://doi.org/10.1111/apt.15087
doi: 10.1111/apt.15087
pubmed: 30600540
Wester A, Ndegwa N, Hagström H (2022) Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2022.05.048
doi: 10.1016/j.cgh.2022.05.048
pubmed: 36257510
López-Larramona G, Lucendo AJ, González-Delgado L (2013) Alcoholic liver disease and changes in bone mineral density. Rev Española Enfermedades Dig 105:609–621. https://doi.org/10.4321/s1130-01082013001000006
doi: 10.4321/s1130-01082013001000006
Malik P, Gasser RW, Kemmler G et al (2009) Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res 33:375–381. https://doi.org/10.1111/j.1530-0277.2008.00847.x
doi: 10.1111/j.1530-0277.2008.00847.x
pubmed: 19053976
Jadzic J, Milovanovic P, Cvetkovic D et al (2021) Mechano-structural alteration in proximal femora of individuals with alcoholic liver disease: Implications for increased bone fragility. Bone 150:116020. https://doi.org/10.1016/j.bone.2021.116020
doi: 10.1016/j.bone.2021.116020
pubmed: 34044170
Pereira F, Azevedo R, Linhares M et al (2021) Hepatic osteodystrophy in cirrhosis due to alcohol-related liver disease. Rev Esp Enfermedades Dig 113:563–569. https://doi.org/10.17235/reed.2020.7301/2020
doi: 10.17235/reed.2020.7301/2020
González-Calvin JL, Mundi JL, Casado-Caballero FJ et al (2009) Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab 94:4844–4850. https://doi.org/10.1210/jc.2009-0835
doi: 10.1210/jc.2009-0835
pubmed: 19897681
Robeva R, Mladenović D, Vesković M et al (2021) The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 151:22–30. https://doi.org/10.1016/j.maturitas.2021.06.012
doi: 10.1016/j.maturitas.2021.06.012
pubmed: 34446275
Chen DZ, Xu QM, Wu XX et al (2018) The combined effect of nonalcoholic fatty liver disease and metabolic syndrome on osteoporosis in postmenopausal females in eastern China. Int J Endocrinol. https://doi.org/10.1155/2018/2314769
doi: 10.1155/2018/2314769
pubmed: 30647739
pmcid: 6311882
Cui R, Sheng H, Rui XF et al (2013) Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. Int J Endocrinol. https://doi.org/10.1155/2013/396545
doi: 10.1155/2013/396545
pubmed: 23983685
pmcid: 3747470
Lee SH, Yun JM, Kim SH et al (2016) Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. J Endocrinol Invest 39:1329–1336. https://doi.org/10.1007/s40618-016-0528-3
doi: 10.1007/s40618-016-0528-3
pubmed: 27561910
Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A (2017) Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis. J Bone Miner Metab 35:685–693. https://doi.org/10.1007/s00774-016-0807-2
doi: 10.1007/s00774-016-0807-2
pubmed: 27928661
Jadzic J, Djonic D (2023) Bone loss in chronic liver diseases: Could healthy liver be a requirement for good bone health? World J Gastroenterol 29:825–833. https://doi.org/10.3748/wjg.v0.i0.0000
doi: 10.3748/wjg.v0.i0.0000
pubmed: 36816627
pmcid: 9932432
Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania AG, Messina C, Napoli N, Mazziotti G (2023) Bone quality in endocrine diseases: determinants and clinical relevance. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02056-w
doi: 10.1007/s40618-023-02056-w
pubmed: 37031450
Bjarnason NH, Sarkar S, Duong T et al (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930. https://doi.org/10.1007/s001980170020
doi: 10.1007/s001980170020
pubmed: 11808544
Sarkar S, Mitlak BH, Wong M et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10. https://doi.org/10.1359/jbmr.2002.17.1.1
doi: 10.1359/jbmr.2002.17.1.1
pubmed: 11771654
Fonseca H, Moreira-Gonçalves D, Coriolano HJA, Duarte JA (2014) Bone quality: the determinants of bone strength and fragility. Sport Med 44:37–53. https://doi.org/10.1007/s40279-013-0100-7
doi: 10.1007/s40279-013-0100-7
Chappard D, Plantard B, Petitjean M et al (1991) Alcoholic cirrhosis and osteoporosis in men: a light and scanning electron microscopy study. J Stud Alcohol 52:269–274. https://doi.org/10.15288/jsa.1991.52.269
doi: 10.15288/jsa.1991.52.269
pubmed: 2046377
Wakolbinger R, Muschitz C, Scheriau G et al (2019) Bone microarchitecture and bone turnover in hepatic cirrhosis. Osteoporos Int 30:1195–1204. https://doi.org/10.1007/s00198-019-04870-6
doi: 10.1007/s00198-019-04870-6
pubmed: 30788527
pmcid: 6546655
Danford CJ, Trivedi HD, Bonder A (2019) Bone health in patients with liver diseases. J Clin Densitom. https://doi.org/10.1016/j.jocd.2019.01.004
doi: 10.1016/j.jocd.2019.01.004
pubmed: 31146965
Jadzic J, Cvetkovic D, Tomanovic N et al (2020) The severity of hepatic disorder is related to vertebral microstructure deterioration in cadaveric donors with liver cirrhosis. Microsc Res Tech. https://doi.org/10.1002/jemt.23642
doi: 10.1002/jemt.23642
pubmed: 33170963
Jadzic J, Tomanovic N, Djukic D et al (2022) Micro - scale assessment of bone quality changes in adult cadaveric men with congestive hepatopathy. Histochem Cell Biol. https://doi.org/10.1007/s00418-022-02128-7
doi: 10.1007/s00418-022-02128-7
pubmed: 35849203
Cohen A, Dempster DW, Recker RR et al (2013) Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab 98:2562–2572. https://doi.org/10.1210/jc.2013-1047
doi: 10.1210/jc.2013-1047
pubmed: 23515452
pmcid: 3667251
Jadzic J, Milovanovic PD, Cvetkovic D et al (2022) The altered osteocytic expression of connexin 43 and sclerostin in human cadaveric donors with alcoholic liver cirrhosis: Potential treatment targets. J Anat. https://doi.org/10.1111/joa.13621
doi: 10.1111/joa.13621
pubmed: 34978341
Dempster DW, Compston JE, Drezner MK, et al (2013) Standardized nomenclature , symbols , and units for bone histomorphometry : a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. 28:1–16. https://doi.org/10.1002/jbmr.1805
Mantovani A, Sani E, Fassio A et al (2019) Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes Metab 45:347–355. https://doi.org/10.1016/j.diabet.2018.10.001
doi: 10.1016/j.diabet.2018.10.001
pubmed: 30315891
Danford CJ, Trivedi HD, Papamichael K et al (2018) Osteoporosis in primary biliary cholangitis. World J Gastroenterol 24:3513–3520. https://doi.org/10.3748/wjg.v24.i31.3513
doi: 10.3748/wjg.v24.i31.3513
pubmed: 30131657
pmcid: 6102495
Mellinger JL (2019) Epidemiology of alcohol use and alcoholic liver disease. Clin Liver Dis 13:136–139. https://doi.org/10.1002/cld.806
doi: 10.1002/cld.806
Cheemerla S, Balakrishnan M (2021) Global epidemiology of chronic liver disease. Clin Liver Dis 17:365–370. https://doi.org/10.1002/cld.1061
doi: 10.1002/cld.1061
Siqueira M de MLG, Casulari LA, de FREITAS WM, et al (2022) Risk factors associated with fracture of the lumbosacral spine and its compromise in the quality of life of cirrhotics. Arq Gastroenterol 59:9–15. https://doi.org/10.1590/S0004-2803.202200001-03
Wang Y, Wen G, Zhou R et al (2018) Association of nonalcoholic fatty liver disease with osteoporotic fractures: a cross-sectional retrospective study of Chinese individuals. Front Endocrinol (Lausanne) 9:1–9. https://doi.org/10.3389/fendo.2018.00408
doi: 10.3389/fendo.2018.00408
Luo Z, Liu Y, Liu Y et al (2017) Cellular and molecular mechanisms of alcohol-induced osteopenia. Cell Mol Life Sci 74:4443–4453. https://doi.org/10.1007/s00018-017-2585-y
doi: 10.1007/s00018-017-2585-y
pubmed: 28674727
Gaddini GW, Turner RT, Grant KA, Iwaniec UT (2016) Alcohol: a simple nutrient with complex actions on bone in the adult skeleton. Alcohol Clin Exp Res 40:657–671. https://doi.org/10.1111/acer.13000
doi: 10.1111/acer.13000
pubmed: 26971854
pmcid: 4918769
Filip R, Radzki RP, Bieńko M (2018) Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging 13:1879–1891. https://doi.org/10.2147/CIA.S170533
doi: 10.2147/CIA.S170533
pubmed: 30323574
pmcid: 6174895
Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238. https://doi.org/10.1002/jbmr.320
doi: 10.1002/jbmr.320
pubmed: 21254230
Maurel DB, Benaitreau D, Jaffré C et al (2014) Effect of the alcohol consumption on osteocyte cell processes: a molecular imaging study. J Cell Mol Med 18:1680–1693. https://doi.org/10.1111/jcmm.12113
doi: 10.1111/jcmm.12113
pubmed: 23947793
Albakheet SS, Yoon H, Shin HJ et al (2020) Bone marrow fat change in pediatric patients with non-alcoholic fatty liver disease. PLoS ONE 15:1–10. https://doi.org/10.1371/journal.pone.0234096
doi: 10.1371/journal.pone.0234096